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Objectives: The conservative versus therapeutic approach to type II endoleak after endovascular repair of abdominal aortic
aneurysm (EVAR) has been controversial. The purpose of this study was to evaluate the safety and cost-effectiveness of
the conservative approach of embolizing type II endoleak only when persistent for more than 6 months and associated
with aneurysm sac growth of 5 mm or more.
Methods: Data for 486 consecutive patients who underwent EVAR were analyzed for incidence and outcome of type II
endoleaks. Spiral computed tomography (CT) scans were reviewed, and patient outcome was evaluated at either office
visit or telephone contact. Patients with new or late-appearing type II endoleak were evaluated with spiral CT at 6-month
intervals to evaluate both persistence of the endoleak and size of the aneurysm sac. Persistent (>6 months) type II
endoleak and aneurysm sac growth of 5 mm or greater were treated with either translumbar glue or coil embolization of
the lumbar source, or transarterial coil embolization of the inferior mesenteric artery.
Results: Type II endoleaks were detected in 90 (18.5%) patients. With a mean follow-up of 21.7  16 months, only 35
(7.2%) patients had type II endoleak that persisted for 6 months or longer. Aneurysm sac enlargement was noted in 5
patients, representing 1% of the total series. All 5 patients underwent successful translumbar sac embolization (n 4) or
transarterial inferior mesenteric artery embolization (n  4) at a mean follow-up of 18.2  8.0 months, with no
recurrence or aneurysm sac growth. No patient with treated or untreated type II endoleak has had rupture of the
aneurysm. The mean global cost for treatment of persistent type II endoleak associated with aneurysm sac growth was
$6695.50 (hospital cost plus physician reimbursement). Treatment in the 30 patients with persistent type II endoleak but
no aneurysm sac growth would have represented an additional cost of $200,000 or more. The presence or absence of a
type II endoleak did not affect survival (78% vs 73%) at 48 months.
Conclusions: Selective intervention to treat type II endoleak that persists for 6 months and is associated with aneurysm
enlargement seems to be both safe and cost-effective. Longer follow-up will determine whether this conservative approach
to management of type II endoleak is the standard of care. (J Vasc Surg 2004;39:306-13.)
Endovascular abdominal aneurysm repair (EVAR) has
been performed for more than a decade worldwide. This
less invasive method of abdominal aortic aneurysm (AAA)
repair continues to gain popularity, despite significant com-
plications with the first-generation devices.1,2 Data from
the US Food and Drug Administration (FDA) trials for
almost 6 years demonstrate acceptable results and an overall
low rate of short-term and mid-term complications.3 En-
doleak has been described as the Achilles heel of EVAR.
Various clinical strategies to effectively treat it and other
complications of EVAR have been published.1,4-6 Despite
consensus on the management of type I and type III
endoleak, controversy remains about the best strategy for
treatment of type II endoleak, which can be found short-
term in about 20% of EVAR.7-12 In addition to the high
incidence of early type II endoleak, late-appearing type II
endoleak is also encountered, which underlines the impor-
tance of long-term surveillance.8,12
Aggressive treatment strategies have been proposed
and widely accepted for treatment of type I and type III
endoleak. Failure to obliterate these endoleaks can result in
aneurysm rupture.8,13 On the other hand, the effect of type
II endoleak in aneurysm rupture has not been clearly de-
fined. Some investigators recommend aggressive treatment of
type II 2 endoleak that persists for 6 months or longer14-16;
others limit treatment of type II endoleak to those associ-
ated with growth of the aneurysm sac.1,8,12,17 We have
followed the conservative approach to management of type
II endoleak, and have instituted embolization procedures
of type II endoleak that persists for more than 6 months
and is associated with aneurysm sac growth of 5 mm or
more. We retrospectively analyzed our experience for the
incidence and outcome of type II 2 endoleak in a single
institution over 7 years of EVAR practice.
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METHODS
A retrospective review was performed of 486 consecu-
tive patients (413 male, 73 female) who underwent EVAR
at our institution between April 1, 1996, and April 30,
2003. One hundred forty-three patients (32%) underwent
EVAR as part of an FDA-approved trial. Bifurcated devices
were used in 424 (95%) patients. All patients data were
entered prospectively in an endoluminal database devel-
oped at our institution, with preoperative, intraoperative,
and postoperative data sets. Follow-up information was
obtained from clinic visit data, telephone calls, or referring
primary care physician office notes. Devices used in the 486
patients evaluated included AneuRx (Medtronic/AVE,
Santa Rosa, Calif; n 335), Ancure (Guidant, Menlo Park,
Calif; n  74), Excluder (W. L. Gore and Associates,
Flagstaff, Ariz; n 36), Talent (Medtronic/AVE; n 22),
Zenith (Cook, Bloomington, Ind; n 15), and Endologix
(Endologix, Irvine, Calif; n  4).
Follow-up for detection of type II endoleak included
thin-cut (1-3 mm) spiral computed tomography per clinical
trial protocol and for commercially available devices at
minimum intervals of 1, 6, and 12 months, and yearly
thereafter. In all clinical trial protocol patients spiral CT was
performed at our institution or at an outside facility, with
the standard protocol for endograft evaluation. Follow-up
CT of the commercially implanted endografts was similarly
performed, primarily at our institution, although the num-
ber of outside CT procedures was higher in this group. In
patients who demonstrated persistent type II endoleak for
6 months or longer or new type II endoleak appearing late,
spiral CT was performed at 6-month intervals to evaluate
the presence of endoleak and aneurysm sac size. The max-
imal diameter of the aneurysm was measured with elec-
tronic calipers and compared with the largest diameter from
the previous study. All patients with renal insufficiency
(serum creatinine concentration 1.8 mg/dL) were fol-
lowed up with non-contrast-enhanced CT and duplex ul-
trasound scanning, also at 1, 6, and 12 months, and yearly
thereafter.
Before treating presumed type II endoleak, detailed
transfemoral arteriography was performed, with selective
injection of the hypogastric arteries and the superior mes-
enteric artery to evaluate lumbar and inferior mesenteric
artery contribution to the endoleak and to rule out an
attachment site leak (type I) or a leak arising from the
endograft itself (type III).
Twenty hours after identifying the type II endoleak at
transfemoral arteriography, a translumbar approach to type
II endoleak ablation was performed. To access the aneu-
rysm sac through a translumbar approach, the patient was
placed prone on the angiography table. Intravenous seda-
tion and pre-procedural antibiotic therapy for coverage
against skin contaminants were administered. A suitable
site for puncture of the aneurysm sac was selected on the
basis of careful analysis of the most recent CT scan. The
goal was to enter the largest area of active flow. Either the
left or right side was used, depending on the position of the
targeted area within the sac. An 18-gauge, 15-cm long
trocar needle was directed from the flank toward the en-
dograft with C-arm fluoroscopic guidance. Free aspiration
of arterial blood or pulsatile flow from the needle confirmed
the proper location of the needle tip. Contrast-enhanced
angiography of the aneurysm sac was then performed to
delineate the sac anatomy and flow lumen (Fig 1). Partic-
ular attention was paid to any possible communication with
the anterior spinal artery. In one patient, visualization of
the anterior spinal artery at arteriography led to direct
coiling of the lumbar branches, rather than using glue.
The volume of contrast agent necessary to fill the
flowing portion of the aneurysm sac, with reflux into the
feeding lumbar arteries, was estimated. NBCA glue (Trufill;
Cordis Endovascular, Miami Lakes, Fla) was prepared ac-
cording to the manufacturer’s instructions, typically in a
dilution of 1 mL of glue and 2 mL of ethiodized oil
(Ethiodol). The needle was cleared with dextrose solution
to prevent polymerization of the glue. The syringe contain-
ing the glue was directly attached to the needle, and the
glue was injected. The needle was removed, and the patient
was observed for signs of neurologic change and bleeding.
Most patients were observed overnight, but occasionally
they were discharged later on the same day.
One patient had a type II endoleak due to a patent
inferior mesenteric artery, which was treated by embolizing
Fig 1. Translumbar angiogram demonstrates lumbar arteries and
type II endoleak.
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the inferior mesenteric artery at its origin (Fig 2). This was
done with a microcatheter, from a retrograde approach
through the superior mesenteric artery. Occlusion was per-
formed with microcoils and standard endovascular tech-
niques. Care was taken to avoid embolization beyond the
branch point of the inferior mesenteric artery into the
superior hemorrhoidal and left colic arteries, to minimize
the risk for colonic ischemia. Glue was never used in this
situation, because of the potential for nontarget emboliza-
tion of this liquid agent.
Operating costs for the five patients who underwent
treatment of type II endoleak associated with aneurysm sac
growth were obtained from the hospital financial depart-
ment. Costs were assigned to room care, pharmacy, radio-
logic services, laboratory services, and material manage-
ment/center processing. Costs were calculated with an
HBO Trendstar database, with cost-to-charge ratios. Pa-
tients with similar hospital stay and procedures will incur
similar costs. Physician (professional fee) reimbursement
was obtained from the business office of the department of
radiology. The mean of the costs and physician reimburse-
ment (global costs) were calculated and used for determin-
ing cost-savings projections.
Patient data were entered on an Excel spreadsheet.
Statistical analyses were performed with SAS version 8.1
software (1999; SAS Institute, Cary, NC). Survival curves
were generated with the Kaplan-Meier method. When the
independent variable had two levels, the Wilcoxon 2 test
was used (comparison of type II endoleak prevalence by
device). The difference in endoleaks by device was also
analyzed with logistic regression analysis.
RESULTS
The 486 patients reviewed underwent 1204 spiral CT
procedures (2.5 CT scans per patient). Forty-three patients
(8.8%) underwent spiral CT at outside institutions, but
films were available for review. type II endoleak was de-
tected in 90 (18.5%) patients at some time during fol-
low-up (Table I). Mean follow-up for the total group was
21.7  16 months (range, 1-84 months). Eighty-one
(17%) patients were followed up for 3 years, and 31 (7%)
patients were followed up for 4 years. Only 35 (7.2%)
patients had type II endoleak that persisted for 6 months or
longer. Among currently commercially available devices,
the The rate of persistent type II endoleak rate was signifi-
cantly higher (P .05) with the Excluder device than with
the AneuRx or Ancure devices. Logistic regression analysis
showed that the odds ratio (OR) for AneuRx compared
with Excluder was 0.15 (95% confidence interval [CI],
0.06-0.37), and the OR for Ancure versus Excluder was
0.31 (95% CI, 0.11-0.93).
Aneurysm sac enlargement was identified in 5 (An-
euRx, n  4; Excluder, n  1) of the 35 patients with
persistent type II endoleak, representing 1% of the total
series. One patient early in the series was treated for inferior
mesenteric artery type II endoleak with no aneurysm sac
growth. The procedure was aborted for technical reasons,
with only two coils in inferior mesenteric artery. In this
patient recurrent inferior mesenteric artery type II endoleak
with aneurysm sac growth developed, and successful infe-
rior mesenteric artery transarterial coil embolization was
performed (Fig 2). The increase in aneurysm sac diameter
was 5 mm or greater in the five patients with persistent type
II endoleak, and occurred at a mean of 16.2 6.7 months
postoperatively (Table II).
Four of the five patients with persistent type II en-
doleak underwent translumbar embolization of the lum-
bar-fed endoleak. Three patients with persistent type II
endoleak underwent glue embolization. One patient, be-
cause of spinal artery communication with the lumbar
artery responsible for the persistent type II endoleak, un-
derwent successful coil embolization of both lumbar arter-
ies feeding the aneurysm sac. All five patients are alive and
well, with no evidence of leak recurrence. The type II
endoleak was successfully treated in all patients at a mean
follow-up of 18.2  8.0 months (range, 6-26 months).
The mean global cost for treatment in the five patients
with type II endoleak and aneurysm growth was $6695.50
(hospital cost, $4869.00; physician reimbursement,
$1826.50). No procedure-related complications occurred
in the five patients with type II endoleak embolization.
Two patients were discharged the same day of the proce-
dure, two were discharged 24 hours post-procedure, and
one was discharged 48 hours post-procedure.
The overall postoperative (30-day or in-hospital) death
rate in patients undergoing EVAR was 1.9%, which com-
pares favorably with open repair series. The overall patient
survival rate at 5 years for the entire cohort was 73%. The
presence or absence of type II endoleak did not affect
Fig 2. Successful transarterial coil embolization of recurrent infe-
rior mesenteric artery type II endoleak.
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patient survival (Fig 3). In patients with type II endoleak
48-month survival was 78%, compared with 73% in those
with no type II endoleak. No aneurysm rupture in patients
with type II endoleak occurred in our series.
DISCUSSION
Treatment of type II endoleak continues to be one of
the most controversial topics in the rapidly developing field
of endovascular treatment of AAA. These endoleaks occur
in 5% to 20% of patients who undergo EVAR.7-12 In our
experience, the rates and long-term existence of type II
endoleaks seem to depend on the type of endovascular graft
used for EVAR. Our extensive experience includes pre-
dominantly the currently FDA-approved devices (Ancure,
AneuRx, Excluder). Of these, the Excluder graft is associ-
ated with the highest rate of type II endoleak; type II
endoleak will develop in 39% of patients at some time
during follow-up. In addition, the Excluder graft has a
significantly (P  .05) higher rate (25%) of persistent (6
months) type II endoleaks, compared with the AneuRx
(4.8%) and Ancure (9.4%) grafts (Table I). These findings
are consistent with those of Ouriel et al,18 who suggest that
the Excluder graft is associated with a higher rate of type II
endoleaks and a decreased rate of aneurysm regression
compared with other endovascular grafts.18-20
Some investigators have suggested that early interven-
tion for type II endoleak is the most appropriate strate-
gy.14-16 The arguments for early intervention include sac
pressurization by type II endoleaks, continued risk for
rupture with persistent type II endoleaks, limitations of
spiral CT to identify type II endoleaks, safety of the inter-
ventions used to treat type II endoleaks, and improved
patient compliance associated with a less rigorous fol-
low-up schedule. Baum et al14 published their experience
with sac pressurization secondary to endoleaks after AAA
repair. They obtained intrasac pressure measurements in 21
patients postoperatively. Eighty-one percent (17 of 21) of
patients had systemic intrasac pressure, and most of these
patients (15 of 17) had type II endoleaks, whereas the
others (2 of 17) had type I endoleaks. Of interest, pressure
measurements obtained postoperatively in 2 patients with
no detectable endoleak also revealed systemic pressure,
rendering the significance of intrasac pressure measure-
ments uncertain. Other authors argue against early treat-
ment, because spontaneous sealing of type II endoleak has
been reported to occur within the first 6 months in as many
as 53% of all endoleaks.1,17,21-24 Additional data support-
ing the clinical significance of retrograde perfusion of an-
eurysm sacs from branch vessels comes from Albany Med-
ical Center. Over 14 years they treated 1218 AAAs with
their technique of aneurysm exclusion.25 The excluded
aneurysm sacs were followed up long-term with duplex
ultrasound scanning, and 4% of patients had persistent
branch flow into the excluded sac. It is interesting that in
64% of patients with persistent sac flow the aneurysm
enlarged, and 26% of enlarged aneurysms ruptured. How
applicable these data are to type II endoleak after EVAR is
uncertain. In no EVAR series has the presence of type II
endoleak been associated with AAA expansion rates or
rupture rates anywhere near as high as those in the Albany
open AAA exclusion series. It must be acknowledged that
our patients were followed up for a much shorter time than
Table I. Type II endoleak detected during follow-up
Device
No. of
patients
Mean follow-up
(mo)
Patients with any
type II endoleak
Patients with
persistent type II
endoleak Mean follow-up
(mo) persistent
type II endoleakn % n %
AneuRx 335 17.8 51 15.2 16 4.8 32
Ancure 74 45 21 28.4 7 9.4 55
Excluder 36 24.5 14 39 9 25 27
Talent 22 4.0 1 4.5 0 0 0
Zenith 15 10 1 6.6 1 6.6 13
Endologix 4 12.5 2 50 2 50 15
Total 486 21.7 90 18.5 35 7.2 33
Table II. Summary of patients with type II endoleak and aneurysm sac growth 5 mm or greater
Patient
Preoperative
AAA size (cm)
Increase in
AAA size (cm)
Origin of type
II endoleak
Time of AAA size
increase (mo) Procedure
Follow-up since
embolization
(mo)
1 5.4 0.8 L 7 TL glue 16
2 5.8 0.7 L 22 TL glue 26
3 4.4 1.3 L 11 TL coils 18
4 5.8 1.5 IMA 21 TA coils 25
5 6.5 0.7 L 20 TL glue 6
AAA, abdominal aortic aneurysm; L, lumbar; IMA, inferior mesenteric artery; TL, translumbar; TA, transarterial.
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the Albany series, which may account for the difference in
rupture rates. Bernhard et al13 published a literature review
of aneurysm ruptures after EVAR, and reported 47 aneu-
rysm ruptures, with operative mortality of 41%. In this
group of patients, two (4%) ruptures after EVAR were
associated with type II endoleaks. Based on our review of
the literature, four AAA ruptures associated with type II
endoleak have been reported. Two of these type II en-
doleaks were associated with untreated aneurysm sac
growth26,27; for the other two, no comment was made as to
aneurysm sac status.2 Other unreported anecdotal cases of
aneurysm rupture associated with type II endoleak have
been quoted, but the aneurysm sac size at the time of
rupture is unknown. Bade et al28 reported a hypogastric
aneurysm rupture from endotension presumed to caused
by a thrombosed type II endoleak.
At this time, spiral CT is considered the gold standard
for long-term evaluation of EVAR. The sensitivity and
specificity of spiral CT in the diagnosis of endoleak has been
questioned.12,29-31 Spiral CT scans are helpful in evalua-
tion of the aneurysm repair and associated anatomy, but the
test is operator-dependent and technique-dependent. En-
doleak, especially type II endoleak, can easily be missed
with incomplete studies. Even excellent quality studies may
not differentiate the type of endoleak.32,33 Baum et al14
reported that 2 of 17 patients with known endoleaks with a
pressurized sac had negative findings at CT and angiogra-
phy as part of the initial evaluation. Parent et al12 suggested
that duplex scanning may be better than CT for evaluation
of endoleaks. In their experience, in a group of patients
with known endoleaks, color duplex ultrasound scanning
enabled diagnosis of 43% of endoleaks, whereas CT en-
abled diagnosis of only 21% of endoleaks. Color duplex
untrasound scans also identified the source of the endoleak
in 100% of cases, whereas CT scans demonstrated the
source of the endoleak in only 19% of cases. However, color
duplex ultrasound scanning is also extremely operator-
dependent. A prospective evaluation of CT and magnetic
resonance angiography (MRA) versus selective angiogra-
phy suggests that MRA in experienced hands is better than
CT for evaluation of type II endoleaks. MRA recognized
type II endoleak in 94% of cases, whereas CT recognized a
significantly smaller number, 50% (P  .05).34 Each insti-
tution will need to evaluate and validate their follow-up
imaging approach on the basis of available expertise and
equipment. We have found spiral CT with delayed repeat
imaging to be sensitive in detection of endoleaks. These
studies suggest that no method is really the gold standard
for evaluation of type II endoleaks, but that a combination
of methods, even in experienced hands, is needed to diag-
nose, and treat if necessary, type II 2 endoleak.
Early intervention for type II endoleaks may avoid the
risk for aneurysm enlargement and rupture and the need for
other diagnostic evaluations, which may not be so accurate
as necessary. An aggressive approach has been suggested by
Baum et al on the basis of their experience.14 If a patient has
Fig 3. Cumulative patent survival (Kaplan-Meier method) with (squares) and without (diamonds) type II endoleak.
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a persistent type II endoleak at 6-month follow-up, regard-
less of the size of the aneurysm, a translumbar intervention
is suggested.4 These interventions have been performed
with very low complication rates, in their experience, but it
is still unclear whether they are really necessary. In our
experience with 486 patients who received treatment with a
variety of endovascular devices, the risk for rupture was 0%.
Patients underwent only intervention to treat persistent
(6 months) type II endoleak that was associated with
aneurysm diameter increase 5 mm or greater. Thirty-five
patients had persistent type II endoleaks, but only 5 of
them (1% of all EVAR patients) also had an enlarging
aneurysm. Treatment was successful in all 5 patients. In our
extensive experience, there have been no ruptures associ-
ated with type II endoleaks. This experience has led us to
adopt a more conservative approach to the management of
type II endoleaks, which can be followed up long term with
minimal associated morbidity and mortality and without
the need for an intervention in most patients. Longer
follow-up will be necessary to establish this conservative
approach as the standard of care for type II endoleaks with
no aneurysm sac growth.
The method of treatment of type II endoleaks has
continued to evolve. The initial treatment for branch en-
doleaks was transarterial embolization of these branches via
the feeding collateral vessels, but the results have been
extremely variable.12,35-37 Because of these inconsistent
results and the interest in obtaining direct pressure mea-
surements from the aneurysm sac, a translumbar direct
approach to the aneurysm sac was originally reported by
Baum et al.4 These authors published their experience with
translumbar and transarterial approaches for the evaluation
and treatment of type II endoleaks.4 They treated 33
patients with type II endoleak with 20 transarterial and 13
translumbar interventions. There was a significant differ-
ence (P  .05) in treatment success rates between tech-
niques, with only a 20% success rate with the transarterial
approach versus a 92% success rate with the translumbar
technique. Successful treatments led to intrasac pressure of
30 mm Hg or less, resolution of type II endoleak in
subsequent studies, and shrinkage of the aneurysm. These
finding are consistent with our experience described here,
with success after all translumbar approaches, and the need
to repeat the transarterial inferior mesenteric artery embo-
lization in one patient. These interventions are associated
with a low complication rate, but, like any intervention, are
best performed only when necessary.4 A series of publica-
tions suggest that transarterial and translumbar interven-
tions are not completely free of complications or always
successful.4,35-38 Some complications can be severe, and
include systemic reaction to the medications used, and
embolization of the thrombotic and embolic agents used,
leading to organ ischemia.6 The technique of laparoscopic
branch ligation has been suggested as an alternative for the
treatment of type II endoleaks by some experienced inves-
tigators.38 This laparoscopic approach has not been used as
extensively as translumbar or transarterial techniques, but
could be used in cases of failed embolization. If translumbar
or transarterial embolization is not successful in patients
with aneurysm sac enlargement, open conversion may be
indicated.
The best approach to treatment of type II endoleaks is
one that is safe, effective, and usually, but not always,
cost-effective. The aggressive approach suggested by Baum
et al39-41 leads to a higher rate of expensive interventions
($6695 per intervention at our institution). This approach
may decrease the frequency and need for follow-up CT
scans if the patient has an endoleak-free reconstruction
associated with a regressing aneurysm. Although the fre-
quency of surveillance could be decreased, some method of
assessing endograft and aneurysm size will need to be
continued. Based on our results, we believe the conserva-
tive approach with selective intervention for type II en-
doleak is safe, usually effective, and cost-effective. The
presence or absence of type II endoleak did not affect
patient survival. There was no aneurysm rupture associated
with type II endoleak. Only 5 patients (1%) required an
intervention for a type II endoleak, at a mean cost of $6695
per patient. If all 35 patients with persistent type II en-
doleak had received treatment, the approximate cost would
have been $235,000, not including the cost of any poten-
tial complications associated with the required evaluations
and treatment techniques. The conservative approach led
to cost savings of $200,000 while maintaining the ultimate
safety and efficacy of the original endovascular treatment.
The future evaluation and treatment of type II en-
doleak are likely to change as we learn more about the
developing endovascular techniques. As suggested by our
experience and other published series, type II endoleak is
associated with the type of endovascular graft used.18,20
Advances in endograft materials and design will decrease
the rate of type II endoleaks in the future. Improved
diagnostic methods, including intrasac pressure monitor-
ing devices, and the prophylactic use of thrombogenic
intrasac materials (Spongostan, Onyx) that can be delivered
at the time of the initial graft placement, may aid in the
diagnosis or further decrease the incidence of type II en-
doleak.42 At this time, based on the available evidence, a
conservative approach of selective treatment of persistent
type II endoleaks associated with enlarging aneurysms is
reasonable and cost-effective. Longer follow-up of larger
series with this conservative approach to type II endoleaks is
needed to demonstrate its safety. When intervention is
required to treat type II endoleak, the translumbar access
appears to be the most effective approach.
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DISCUSSION
Dr Christopher K. Zarins (Stanford, Calif). I rise to congrat-
ulate you for an outstanding paper and to support your conclu-
sions.
Our experience is similar to yours, and we have adopted the
same philosophy of not treating type II endoleaks unless there is
significant aneurysm enlargement. We also have had no adverse
effects and no ruptures. We have treated only 9 patients for type II
endoleaks in more than 400 patients with endovascular repair, and
of these, 6 have had recurrence after embolization. I think that
your use of glue may be a significant improvement in those patients
that you treat.
My question relates to where we go from here. If in fact you
don’t need to treat type II endoleaks unless the aneurysm enlarges,
why even look for them? Why not just follow the size of the
aneurysm with ultrasound? And should you find enlargement, then
do further studies with CT and proceed with treatment.
We did a retrospective analysis of our own experience, with
this idea in mind. We found that if we had used only ultrasound for
follow-up evaluation, we would have avoided 86% of CT scans and
would not have missed a single adverse event.
Dr Eric Steinmetz. I thank Dr Zarins for his comments.
I think duplex scan is probably an accurate tool to track
endoleaks, and may be easier to assess type II endoleaks. So I agree
with you that if you have a good noninvasive laboratory, this may
be the best and cost-effective approach.
Dr Peter R. Bell (Leicester, England). You said that type II
endoleaks were not dangerous, and yet you have been treating the
aneurysms when they enlarge. What evidence is there that enlarge-
ment is dangerous in that situation?
I’ll remind you of a paper this morning, in the pig, where the
pressure was no higher than 50 mm Hg in that model with the side
branches open.
Second, I can’t understand why you think they’re device-
related. How can that be?
Dr Steinmetz. I’m going to answer the second question
about the device relation. Dr Ken Ouriel, as well as other authors,
have observed similar findings of differential of type II endoleaks
with different devices. I am not aware that there is a good expla-
nation for this.
Could you please repeat the first question.
Dr Bell. You said that type II endoleaks didn’t rupture, but
then you treated a few because they enlarged. What evidence is
there that that is a good thing to do?
Dr Steinmetz. We think that enlargement is probably a
dangerous sign, and have used that as an indicator for treatment.
Dr Bell. What evidence is there for that? Thank you.
Dr Steinmetz. Aneurysm enlargement has been the main
indicator to offer either surgical or endovascular treatment. This
data is based on open repair versus surveillance studies, both in
Europe and the United States. Both studies demonstrated 5.5 cm
to be the size at which rupture rates increase. Although this has not
been validated in endografts, there are two cases in the literature of
type II endoleaks causing rupture, and both had sac enlargement
documented before the rupture.
Dr Michel S. Makaroun (Pittsburg, Pa). That was actually a
very enjoyable paper, especially when it actually confirms your
prejudices.
I have a few questions for you.
Were all the CT procedures done at your institution? And did
you have the chance to review the scans yourself? And, in light of
the presentation that just preceded yours, how sure are you that the
patients you did not treat and classified as having a type II endoleak
truly had type II endoleaks?
In your cost analysis, you somehow skipped the extra cost that
you’ve been putting your patients through by actually bringing
them in much more frequently for CT and the visits. Can you
comment on that, please.
Dr Steinmetz. So, about the cost, yes, we found out that the
cost of one CT would be around $1000 in our institution. So if we
decide to follow up patients and not treat them for type II
endoleaks, that means one more CT scan a year. That means $1000
more a year. So if you have to follow up this person for several
years, at the end maybe cost can be an issue. As suggested by Dr
Zarins, maybe duplex ultrasound scanning will be a less expensive
method of follow-up in these patients, since all we need to monitor
is aneurysm sac size and make certain it is not a type I endoleak.
Regarding the higher rate of type II endoleaks in our series,
the number of Excluder cases in our series is relatively small, so that
although there is a statistically higher incidence compared with
other endografts, this may be a type II error effect.
Dr Makaroun. How sure are you that the others are truly type
II endoleaks?
Dr Steinmetz. The others?
Dr Makaroun. Since you based your diagnosis only on CT
scans, how sure are you that you’re treating type II endoleaks, the
ones that never had an arteriogram?
Dr Steinmetz. Although CT may not be the best method to
identify endoleaks, we believe that any suggestion of early sac
filling or the presence of a large endoleak seen early in the image
acquisition should undergo angiography to verify whether it is a
type II or a type I endoleak. This was necessary in four patients.
Three of the four had type I endoleaks.
Dr Ronald M. Fairman (Philadelphia, Pa). Along the same
lines, I just want to clarify the pathway here to make sure I
understand this. You took a conservative course for at least 6
months. And if the aneurysm enlarged, they you shifted over to a
treatment pathway. As part of the treatment pathway, did patients
ever undergo diagnostic arteriography? Or did you go right to
embolization without a diagnostic arteriogram?
Dr Steinmetz. Yes, if the aneurysm sac grew, then a diagnostic
arteriogram was obtained.
Dr Fairman. So all the patients had a diagnostic arteriogram
then, all five?
Dr Steinmetz. Yes, exactly.
Dr Fairman. And were there any changes in classification as a
result of the arteriogram?
Dr Steinmetz. Among those five patients, no.
Dr Fairman. One other question. Do you have any informa-
tion you can give us about the size of the aneurysms that you were
following up? Clearly, if we have somebody who has an endoleak
and an 8.5-cm aneurysm, we’re more likely to get an arteriogram
to be sure that in fact it’s a type II endoleak. Do you have any of
that information you could provide for us?
Dr Steinmetz. There is a spectrum of sizes. We have aneu-
rysms 6 cm or greater that were treated with endografts and show
a type II endoleak for more than 6 months. If the sac does not
grow, we use the same approach of close surveillance.
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